Biotech - Spark Newswire

3 minute read

Cue Health Collaborates With Pfizer To Provide People Who Test Positive For COVID-19 With Actionable Health Information To Better Inform their Treatment Journey

Today, 3:03 AM

New educational resources will make it easier for people at high risk of progression to severe COVID-19 to protect their health through accessible and timely health information Cue Health ("Cue")

HLTH

2 minute read

Galectin Therapeutics Provides Final Randomization Status Of NAVIGATE, Its Seamless, Adaptive Phase 2b/3 Study of Belapectin In Patients With Liver Cirrhosis Caused By Non-Alcoholic Steatohepatitis

By Happy Mohamed

Today, 3:03 AM

Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, announced that in late December 2022, it ended the enrollment of new patients into NAVIGATE, its

GALT

2 minute read

BioVie Announces Completion Of Patient Enrollment In Phase 3 Trial Assessing NE3107 In Alzheimer’s Disease

By Happy Mohamed

Today, 3:03 AM

BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced

BIVI

1 minute read

UpHealth Expects FY2023 Revenues Of $127M-$135M Vs. $177.85M Estimate

By Benzinga Newsdesk

Today, 3:03 AM

This represents growth of 5% to 12% over pro forma 2022 revenue of $121 million. For comparison purposes, both the 2023 estimated revenue and 2022 pro forma revenue include five months of

UPH

1 minute read

FDA Fuels Respiratory Syncytial Virus Vaccine Race While Backing GSK’s Candidate Soon After Pfizer’s

By Vandana Singh

Today, 3:03 AM

The FDA’s Vaccines and Related Biological Products Advisory Committee voted that GSK plc’s (NYSE:GSK) available data support the safety and effectiveness of…

GSK

1 minute read

Valneva Announced Additional Data From Remaining Studies And An Update On Regulatory Submissions For Its Inactivated Covid-19 Vaccine, VLA2001.

By Benzinga Newsdesk

Today, 3:03 AM

As previously announced, Valneva will not invest in further development of the vaccine, in the absence of a new partnership1. It is, however, completing remaining clinical studies and submissions as agreed with

VALN

2 minute read

Why Inovio (INO) Shares Are Moving After-Hours

By Henry Khederian

Today, 3:03 AM

After falling initially in after-hours trading on Wednesday, Inovio Pharmaceuticals Inc (NASDAQ: INO) shares are back up following the company report of worse-than-expected fourth-quarter financial results and announced topline results from REVEAL2.

INO

1 minute read

FDA
News

INOVIO Says Phase 2 REVEAL2 Trial Evaluating VGX-3100 Did Not Meet Primary Endpoint

By Benzinga Newsdesk

Today, 3:03 AM

Announces topline results from REVEAL2, the second Phase 3 trial evaluating VGX-3100 as a treatment for cervical high-grade squamous intraepithelial lesions (HSIL) Trial results did not meet the primary endpoint in

INO

2 minute read

Semler Announces Clinical Study Published Using QuantaFlo As An Aid For Diagnosis Of Heart Dysfunction In The Primary Care Setting

By Happy Mohamed

Today, 3:03 AM

Semler Scientific, Inc. (NASDAQ:SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers (HCPs), today announced the publication of a study in

SMLR